SCHEMBL7796497

SCHEMBL7796497

NS(=O)(=O)c1ccc(-c2c(-c3ccc([N+](=O)[O-])cc3)noc2CO)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 7/20 0.74
CA1 P00915 13/20 0.54
CA2 P00918 13/20 0.54
CA12 O43570 9/20 0.54
CA9 Q16790 9/20 0.54
CA14 Q9ULX7 6/20 0.54
CA4 P22748 5/20 0.53
CA7 P43166 5/20 0.53
CA3 P07451 2/20 0.50
CA6 P23280 2/20 0.50
CA5A P35218 2/20 0.50
CA13 Q8N1Q1 2/20 0.50
CA5B Q9Y2D0 2/20 0.50
MT-CO2 P00403 1/20 0.48
LMNA P02545 1/20 0.48
ADRB2 P07550 1/20 0.48
ADRB1 P08588 1/20 0.48
CYP3A4 P08684 1/20 0.48
ADORA3 P0DMS8 1/20 0.48
CHRM1 P11229 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7789652 0.85 PTGS2 (0.81) PTGS2CA1CA2CA12CA9
Hydroxylated Derivative SCHEMBL214649 0.85 PTGS2 (1.00) PTGS2CA1CA2CA12CA9
SCHEMBL7796677 0.81 PTGS2 (0.72) PTGS2CA1CA2CA12CA9
SCHEMBL5983425 0.76 PTGS2 (0.81) PTGS2CA1CA2CA12CA9
Sulfamide SCHEMBL4638969 0.75 PTGS2 (0.82) PTGS2CA1CA2CA12CA9
SCHEMBL4892937 0.75 PTGS2 (0.80) PTGS2CA1CA2CA12CA9
SCHEMBL3863087 0.74 PTGS2 (0.67) PTGS2CA1CA2CA12CA9
SCHEMBL8645623 0.74 PTGS2 (0.63) PTGS2CA1CA2CA12CA9
SCHEMBL8479025 0.74 PTGS2 (0.79) PTGS2CA1CA2CA12CA9
SCHEMBL14267671 0.73 PTGS2 (0.73) PTGS2CA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010055565-A1 Method of detecting cyclooxygenase-2 G.D. SEARLE & CO. (US) 2001-12-27 US claimed
US-6045773-A Method of detecting cyclooxygenase-2 G.D. SEARLE & CO. (US) 2000-04-04 US claimed
EP-0859642-A2 METHOD OF DETECTING CYCLOOXYGENASE-2 G.D. SEARLE & CO. (US) 1998-08-26 EP claimed
WO-1997014679-A2 METHOD OF DETECTING CYCLOOXYGENASE-2 G.D. SEARLE & CO. (US) 1997-04-24 WO claimed
US-20010055565-A1 Method of detecting cyclooxygenase-2 G.D. SEARLE & CO. (US) 2001-12-27 US disclosed
US-6045773-A Method of detecting cyclooxygenase-2 G.D. SEARLE & CO. (US) 2000-04-04 US disclosed
EP-0859642-A2 METHOD OF DETECTING CYCLOOXYGENASE-2 G.D. SEARLE & CO. (US) 1998-08-26 EP disclosed
WO-1997014679-A2 METHOD OF DETECTING CYCLOOXYGENASE-2 G.D. SEARLE & CO. (US) 1997-04-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010055565-A1 Method of detecting cyclooxygenase-2 PTGS2, PTGES2, PTGER2 PTGS2 1/4885CA1 906/4885CA2 221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.